FDA Classifies Endoscopic Traction Devices as Class II Medical Devices
The U.S. Food and Drug Administration (FDA) has published the classification of the Endoscopic Traction Device as a Class II medical device, subject to Special Controls, through the introduction of section 21 CFR 876.4410.
The decision, effective June 22, 2026 (with the classification applicable since June 13, 2022), results from the evaluation carried out under the De Novo process. According to the FDA, Class II classification provides reasonable assurance of safety and effectiveness for this type of device and helps reduce the regulatory burden associated with bringing it to market.
What is an Endoscopic Traction Device?
The FDA identifies this device as a prescription device used endoscopically to retract tissue in the gastrointestinal tract during dissection procedures, increasing visualization of the dissection plane and assisting in tissue resection, exposure, and removal.
Main regulatory requirements
The new classification establishes a set of Special Controls that now apply to this type of device, including:
In vivo performance testing to demonstrate device performance under the intended conditions of use, including evaluation of perforation, hemorrhage, mucosal injury, ease of insertion and removal, visualization during the procedure, and ease of use.
Non-clinical performance testing to demonstrate, among other aspects, proper device function, tissue retraction capability, tensile strength, risk of laceration, dimensional verification, and, where applicable, evaluation of magnet strength and safety.
Usability evaluation to demonstrate that intended users can use the device safely and correctly.
Demonstration of sterility of patient-contacting components.
Demonstration of biocompatibility of patient-contacting components.
Evidence supporting the device's shelf life, including maintenance of sterility, package integrity, and functionality.
Specific labeling requirements, including recommended training for safe use, anatomical locations and lesion dimensions for which the device has been demonstrated to be safe, as well as its shelf life.
The FDA also identifies the main risks associated with this type of device, including adverse tissue reaction, tissue trauma (such as hemorrhage, perforation, or laceration), infection, device failure, and increased procedure and sedation time.
Impact for manufacturers
For manufacturers of endoscopic traction devices, this classification clearly establishes the regulatory requirements applicable to this device category.
Manufacturers will need to demonstrate compliance with the Special Controls defined by the FDA, including performing the required performance testing, usability evaluations, sterility validation, biocompatibility demonstration, and compliance with the labeling requirements set out in the new regulation.
In addition, the FDA states that this type of device remains subject to Premarket Notification (510(k)) requirements, with no exemption granted from this obligation. The agency also notes that the De Novo classification allows this type of device to serve as a reference device (predicate device) for future 510(k) submissions of substantially equivalent devices, reducing the need for new De Novo requests for devices of the same type.
